BiotechTube

Treatment A + Treatment B + Treatment C + Treatment D + Acetaminophen

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)

Conditions

Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants

Trial Timeline

Sep 5, 2018 → Oct 21, 2018

NCT ID
NCT03649165

About Treatment A + Treatment B + Treatment C + Treatment D + Acetaminophen

Treatment A + Treatment B + Treatment C + Treatment D + Acetaminophen is a phase 1 stage product being developed by AstraZeneca for Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs). The current trial status is completed. This product is registered under clinical trial identifier NCT03649165. Target conditions include Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants.

What happened to similar drugs?

0 of 1 similar drugs in Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs) were approved

Approved (0) Terminated (0) Active (1)
🔄SelumetinibAstraZenecaPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03649165Phase 1Completed

Competing Products

20 competing products in Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)

See all competitors
ProductCompanyStageHype Score
SelumetinibAstraZenecaPhase 2
27
SelumetinibAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1
29
AZD2014AstraZenecaPhase 2
35
Selumetinib + PlaceboAstraZenecaPhase 2
27
SelumetinibAstraZenecaPhase 1/2
32
SelumetinibAstraZenecaPhase 1
33
Selumetinib granule formulation + Selumetinib capsule formulationAstraZenecaPhase 1/2
36
SelumetinibAstraZenecaPhase 3
44
Everolimus (RAD001) , Afinitor®NovartisPhase 2
35
RAD001: EverolimusNovartisPhase 2
35
RAD001, everolimusNovartisPhase 2
27
TasignaNovartisPhase 1
29
TrametinibNovartisPhase 2
39
Everolimus (RAD001)NovartisPhase 2
27
Sutent®/SunitinibPfizerPhase 2
27
Sorafenib (Nexavar)BayerPhase 2
24
PTC299United TherapeuticsPhase 2
24
REC-2282 + PlaceboRecursion PharmaceuticalsPhase 2/3
24
BinimetinibPacific BiosciencesPhase 2
25